NCT01660399 is a Phase 2 clinical trial of Boanmycin in Squamous Cell Lung Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT01660399?

NCT01660399 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT01660399?

Interventions in NCT01660399: Boanmycin, Docetaxel.

What condition does NCT01660399 study?

NCT01660399 studies Squamous Cell Lung Cancer.

Is NCT01660399 still recruiting?

NCT01660399 is currently status unknown. Last updated 21 December 2015.

Last reviewed 2015-12-21 · How we verify

NCT01660399

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial

Status unknown Phase 2 Last updated 21 December 2015

What this trial tests

Phase 2 trial testing Boanmycin in Squamous Cell Lung Cancer in 300 participants. Status unknown.

Timeline

1 August 2012

Primary endpoint
1 November 2016

1 December 2016

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	300
Start date	1 August 2012
Primary completion	1 November 2016
Estimated completion	1 December 2016
Sites	1 location across China

Drugs / interventions tested

Boanmycin — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Squamous Cell Lung Cancer — all drugs for Squamous Cell Lung Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

18 and older, any sex, with Squamous Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

disease free survival
Time frame: 1.5 years
DFS was defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death.

Sponsor's own description

This predictive, randomized, double-blind, multi-center trial is going to evaluate the efficacy and safety of two regimens of boanmycin plus docetaxel versus docetaxel alone as a second line treatment for chemotherapy for stage IIIb-IV or postoperative recurrent squamous cell lung cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Squamous Cell Lung Cancer

Currently open trials in the same condition.

NCT07444281 — An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Can · Phase 1 · recruiting
NCT05550961 — APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Ther · recruiting
NCT04566432 — Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients · recruiting
NCT03198546 — GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression · Phase 1 · recruiting
NCT01345851 — Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemother · NA · active not recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01660399 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 21 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01660399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing